» Articles » PMID: 7552351

Transport of [125I]transferrin Through the Rat Blood-brain Barrier

Overview
Journal Brain Res
Specialty Neurology
Date 1995 Jun 19
PMID 7552351
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Transferrin receptors are present in the plasma membrane of brain endothelial cells but it is unclear if these receptors mediate transport of transferrin across the blood-brain barrier (BBB). In the present study, the transport of rat holo-transferrin (rTf) across the BBB in vivo was evaluated in ketamine anesthetized rats (250-300 g) both by in situ brain perfusion coupled with capillary depletion analysis and by thaw-mount autoradiography. [125I]rTf was infused through the right internal carotid artery at a rate of 3.65 ml/min for 2.5-5 min. After a 5 min perfusion, the volume of distribution (VD) of [125I]rTf in the brain homogenate, the postvascular supernatant, or the vascular pellet was 55.8 +/- 4.5, 43.5 +/- 4.8, and 8.7 +/- 2.3 microliters/g, respectively. Co-infusion of [125I]rTf with unlabeled rTf or with a high dose of OX26 monoclonal antibody to the rat transferrin receptor significantly reduced the [125I]rTf transport, and in the presence of 10% rat serum [125I]rTf transport was nearly entirely abolished. The transport of [125I]rTf across the BBB in vivo was demonstrated by thaw-mount autoradiography, which showed silver grains well within brain parenchyma following a 5 min internal carotid artery perfusion. These studies are consistent with the following conclusions: (a) in the absence of competing plasma transferrin, [125I]holo-transferrin is transported through the BBB at a rate comparable to the OX26 monoclonal antibody; and (b) the ability to detect measurable transport of perfused [125I]transferrin is greatly inhibited by a small contamination of the perfusate by rat serum, which contains high concentrations of competing transferrin.

Citing Articles

Treatment of Parkinson's disease with biologics that penetrate the blood-brain barrier via receptor-mediated transport.

Pardridge W Front Aging Neurosci. 2023; 15:1276376.

PMID: 38035276 PMC: 10682952. DOI: 10.3389/fnagi.2023.1276376.


Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier.

Pardridge W Front Drug Deliv. 2023; 3.

PMID: 37583474 PMC: 10426772. DOI: 10.3389/fddev.2023.1227816.


Blood-Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles.

Thomsen M, Johnsen K, Kucharz K, Lauritzen M, Moos T Pharmaceutics. 2022; 14(10).

PMID: 36297671 PMC: 9608573. DOI: 10.3390/pharmaceutics14102237.


Identification and Characterization of Elevated Expression of Transferrin and Its Receptor TfR1 in Mouse Models of Depression.

Chang X, Ma M, Chen L, Song Z, Zhao Z, Shen W Brain Sci. 2022; 12(10).

PMID: 36291201 PMC: 9599150. DOI: 10.3390/brainsci12101267.


A Historical Review of Brain Drug Delivery.

Pardridge W Pharmaceutics. 2022; 14(6).

PMID: 35745855 PMC: 9229021. DOI: 10.3390/pharmaceutics14061283.